

Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021

<https://marketpublishers.com/r/CDC25A9FBD5CEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CDC25A9FBD5CEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Hepatitis Delta Virus (HDV) Infection Understanding

Chronic Hepatitis Delta Virus (HDV) Infection: Overview

Chronic Hepatitis Delta Virus (HDV) Infection is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. The virus can transmit from person to person and affect nearly 5% of population with prior HBV infection.

"Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects

across the indication. A detailed picture of the Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis Delta Virus (HDV) Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.

Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters

This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs

Lonafarnib: Eiger Biopharmaceuticals

Eiger's lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.

JNJ-73763989: Janssen Pharmaceuticals

Janssen "breakthrough" drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral

class molecule designed to treat HVB and HVD infection via RNA interference mechanism.

Further product details are provided in the report.....

Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Hepatitis Delta Virus (HDV) Infection

There are approx. 5+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Janssen Pharmaceuticals and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.

Chronic Hepatitis Delta Virus (HDV) Infection Report Insights

Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Hepatitis Delta Virus (HDV) Infection Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Hepatitis Delta Virus (HDV) Infection drugs?

How many Chronic Hepatitis Delta Virus (HDV) Infection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis Delta Virus (HDV) Infection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis Delta Virus (HDV) Infection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Hepatitis Delta Virus (HDV) Infection and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Janssen Pharmaceuticals

Eiger Biopharmaceutical

Pharma Essentia

Key Products

JNJ-73763989

Lonafarinib

P1101

Contents

Introduction

Executive Summary

Chronic Hepatitis Delta Virus (HDV) Infection: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chronic Hepatitis Delta Virus (HDV) Infection – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Chronic Hepatitis Delta Virus (HDV) Infection companies' collaborations, Licensing, Acquisition -Deal Value Trends

Chronic Hepatitis Delta Virus (HDV) Infection Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Lonafarnib: Eiger Biopharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

JNJ-73763989: Janssen Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Chronic Hepatitis Delta Virus (HDV) Infection Key Companies

Chronic Hepatitis Delta Virus (HDV) Infection Key Products

Chronic Hepatitis Delta Virus (HDV) Infection- Unmet Needs

Chronic Hepatitis Delta Virus (HDV) Infection- Market Drivers and Barriers

Chronic Hepatitis Delta Virus (HDV) Infection- Future Perspectives and Conclusion

Chronic Hepatitis Delta Virus (HDV) Infection Analyst Views

Chronic Hepatitis Delta Virus (HDV) Infection Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CDC25A9FBD5CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDC25A9FBD5CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970